Nls Pharmaceutics Ag (NLSPW)

Nls Pharmaceutics Ag (NLSPW) 最新ニュース

NLS Pharmaceutics (NASDAQ:NLSP) Stock Price Up 9.8% - Defense World

Defense World

NLS Pharmaceutics Extends Loan Maturity Date - TipRanks.com - TipRanks

TipRanks

NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the ... - The Globe and Mail

The Globe and Mail

NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - The Globe and Mail

The Globe and Mail

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions - The Globe and Mail

The Globe and Mail

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing - Yahoo Finance

Yahoo Finance

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - AccessWire

AccessWire

NLS Pharmaceutics Extends Loan Maturity Date - TipRanks.com - TipRanks

TipRanks

NLS Pharmaceutics launches $1.75M share and warrant offering - Investing.com

Investing.com

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq - Yahoo Finance

Yahoo Finance

Notice of Deficiency with Nasdaq Continued Listing Requirements - Yahoo Finance

Yahoo Finance

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual ... - Yahoo Finance

Yahoo Finance

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification - Yahoo Finance

Yahoo Finance

NLS Pharmaceutics Announces Company Update on Strategic Partnerships - Yahoo Finance

Yahoo Finance

FDA reviews protocol of NLS Pharmaceutics' study of Mazindol ER - Clinical Trials Arena

Clinical Trials Arena

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of ... - SEC.gov

SEC.gov

NLS Pharmaceutics Announces Company Update Webcast - AccessWire

AccessWire

FDA approves NLS' narcolepsy therapy Phase III programme - Clinical Trials Arena

Clinical Trials Arena

NLS Pharmaceutics to Present at the 35th Annual Roth Conference - The Globe and Mail

The Globe and Mail

NLS Pharmaceutics CEO Issues Letter to Shareholders - December 22, 2022 - BioSpace

BioSpace

NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up ... - AccessWire

AccessWire

NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the ... - The Globe and Mail

The Globe and Mail

NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex ... - PR Newswire

PR Newswire

NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering - PR Newswire

PR Newswire

NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS ... - GlobeNewswire

GlobeNewswire